Literature DB >> 18371163

The spectrum of the factor 8 (F8) defects in Taiwanese patients with haemophilia A.

G-C Ma1, S-P Chang, M Chen, S-J Kuo, C-S Chang, M-C Shen.   

Abstract

Haemophilia A (HA) is an X-linked recessive bleeding disorder caused by various types of pathological defects in the factor VIII gene (F8), which encodes coagulation factor VIII (FVIII). To date, several studies on the spectra of F8 defects have been performed in Western populations, but similar studies in Asian races are scarce. Here, we report the distribution of the mutations within the F8 gene in 31 Taiwanese unrelated HA patients (19 severe and 10 moderate/mild males and two severe females). Of these, 12 (38.7%) and one (3.2%) severe males were genotyped with the recurrent IVS22 and IVS1 inversion, respectively, similar to that in general populations (IVS22: 40-50%; IVS1: 2-5%). The F8 defects in the remaining 18 inversion-negative patients cover a wide spectrum, in which 17 different mutations were identified (10 missense and three nonsense mutations, and two small and two large deletions). Eleven of these mutations are novel: seven caused missense substitutions and four resulted in truncated proteins. To assess the putative pathogenetic impacts of the newly amino acid substitutions, computer analyses were performed based on molecular 3D modelling. The degree of conservation in cross-species FVIIIs and the position in known functional FVIII regions were studied. The novel missense mutations found in our series all occurred at evolutionary conserved residues that may carry a functional importance in our analyses. The results of this study add the short list of Taiwanese/Chinese F8 mutations, and will enhance our understanding of the molecular basis of FVIII function and the mechanism underlying HA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371163     DOI: 10.1111/j.1365-2516.2008.01687.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.

Authors:  Farhad Lotfi; Hamid Talebianpour; Khosro Keshavarz; Fatemeh Emadi; Mohammad Reza Bordbar; Peivand Bastani
Journal:  Daru       Date:  2020-04-22       Impact factor: 3.117

2.  Inhibitors of factor VIII in black patients with hemophilia.

Authors:  Kevin R Viel; Afshin Ameri; Thomas C Abshire; Rathi V Iyer; Raymond G Watts; Charles Lutcher; Cynthia Channell; Shelley A Cole; Karl M Fernstrom; Shelley Nakaya; Carol K Kasper; Arthur R Thompson; Laura Almasy; Tom E Howard
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

Review 3.  Preimplantation genetic diagnosis of hemophilia A.

Authors:  Ming Chen; Shun-Ping Chang; Gwo-Chin Ma; Wen-Hsian Lin; Hsin-Fu Chen; Shee-Uan Chen; Horng-Der Tsai; Feng-Po Tsai; Ming-Ching Shen
Journal:  Thromb J       Date:  2016-10-04

4.  Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population.

Authors:  Maimiza Zahari; Siti Aishah Sulaiman; Zulhabri Othman; Yasmin Ayob; Faraizah Abd Karim; Rahman Jamal
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.